Highlights Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Market Closed - Hong Kong S.E. Other stock markets 04:08:08 2024-06-27 EDT			5-day change	1st Jan Change
5.77 ^HKD	-0.69%		-0.17%	-14.26%

06-25	Simcere-Mabpharm Cancer Drug Gets Marketing Approval in China	MT
06-25	Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Simcere-Mabpharm Cancer Drug Gets Marketing Approval in China	06-25	MT
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China	06-25	CI
Simcere Pharmaceutical Group Limited commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.	06-18	CI
Simcere Pharma Shareholders Approve Up to 500 Million Yuan Share Buyback	06-17	MT
Simcere Pharmaceutical Group Limited's Equity Buyback announced on June 29, 2023, has expired.	06-13	CI
Simcere Pharmaceutical’s Cancer Drug Shows Positive Results	06-03	MT
Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting	06-02	MT
Simcere Pharmaceutical Group Limited Announces Results of the Phase III Clinical Trial of ENZESHU for the Treatment Ofplatinum-Resistant Ovarian Cancer Were Presented at the ASCO Annual Meeting	06-02	CI
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China	05-31	CI
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong	05-22	CI
Simcere Pharmaceutical’ Profit Down 23% in 2023	04-25	MT
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	04-09	MT
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	04-09	CI
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	03-20	MT
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	03-20	CI
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator	03-17	MT
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	03-15	CI
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	03-13	MT
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration	03-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Highlights

Filters